ExcelFin Acquisition Corp. (XFIN) to Combine with Baird Medical in $370M Deal
ExcelFin (NASDAQ:XFIN) has entered into a definitive agreement to combine with device-maker Baird Medical at an enterprise value of $370 million, or 14.6x its 2023E adjusted EBITDA. Guangzhou, China-based Baird produces an ultrasound needle device that allows for less-invasive treatment of thyroid and liver tumors. The combined company is expected to trade on the NasdaqRead More
To access this post, you must purchase 1 - User: Monthly Plan.